Cancer pathogenesis and therapy最新文献

Cover 封面

Cancer pathogenesis and therapy Pub Date : 2024-09-21 DOI: 10.1016/S2949-7132(24)00061-2

引用次数: 0

Corrigendum to “Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology” [Cancer Pathog Ther. 2024;2:205–211] 新一代测序技术在新诊断的多发性骨髓瘤患者中检测到的基因突变》更正 [Cancer Pathog Ther.］

Cancer pathogenesis and therapy Pub Date : 2024-09-14 DOI: 10.1016/j.cpt.2024.09.002

Yutong Wang, Mengzhen Wang, Bin Chu, Minqiu Lu, Lei Shi, Shan Gao, Yuan Chen, Qin Yan, Na Ji, Li Bao

引用次数: 0

Coexistence of myeloproliferative neoplasms with multiple myeloma 骨髓增生性肿瘤与多发性骨髓瘤并存

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/j.cpt.2023.12.001

Qiuqing Xiang, Bin Chu, Minqiu Lu, Lei Shi, Yutong Wang, Lijuan Fang, Yuan Chen, Kai Sun, Li Bao

引用次数: 0

Diagnosis of choroid plexus papilloma: Current perspectives and future directions 脉络丛乳头状瘤的诊断：当前视角和未来方向

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/j.cpt.2023.09.005

Esma'il Akade , Fereshteh Aslani , Kimia Verdi , Mohammad Bahadoram , Gholam Abbas Kaydani

{"title":"Diagnosis of choroid plexus papilloma: Current perspectives and future directions","authors":"Esma'il Akade , Fereshteh Aslani , Kimia Verdi , Mohammad Bahadoram , Gholam Abbas Kaydani","doi":"10.1016/j.cpt.2023.09.005","DOIUrl":"10.1016/j.cpt.2023.09.005","url":null,"abstract":"<div><p>Choroid plexus papilloma (CPP) is a rare, slow-growing, and typically benign brain tumor that predominantly affects children. CPP is characterized by well-defined circular or lobulated masses in the ventricles, leading to symptoms related to increased intracranial pressure and hydrocephalus. CPP diagnosis relies on a combination of clinical presentation, imaging findings, and histological examination. The World Health Organization (WHO) classification categorizes choroid plexus tumors into CPP (Grade І), atypical CPP (aCPP, Grade II), and choroid plexus carcinoma (CPC, Grade III). This article reviewed current diagnostics modalities and explored the emergence of new diagnostic methods for CPP. Research on molecular markers and genetic alterations associated with CPP is ongoing, and some potential markers have been identified. These results offered insights into potential therapeutic targets and personalized treatment approaches for CPP. Advancements in radiomics and liquid biopsy hold promise for improving diagnostic accuracy and monitoring treatment outcomes for choroid plexus tumors. Radiomics can provide quantitative data from imaging studies, whereas liquid biopsy can analyze tumor-derived genetic material and molecular markers from body fluids, such as cerebrospinal fluid (CSF) and blood. The rapidly evolving fields of molecular and genetic research and novel diagnostic methods require continuous updates and advancements before their application in clinical practice. We hope that these advancements will lead to earlier and more precise diagnoses, better treatment options, and improved outcomes in patients with CPP and other brain tumors.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 173-179"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000551/pdfft?md5=bb17f6201eedfa788f475b6b3dbcdd46&pid=1-s2.0-S2949713223000551-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134961973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: A retrospective cohort study based on the SEER database 与转移性外阴癌手术、放疗和化疗相关的总生存率：基于 SEER 数据库的回顾性队列研究

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/j.cpt.2023.08.003

Xiaolin Meng , Shuaiqingying Guo , Xue Feng , Jihui Ai , Jie Yang

{"title":"Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: A retrospective cohort study based on the SEER database","authors":"Xiaolin Meng , Shuaiqingying Guo , Xue Feng , Jihui Ai , Jie Yang","doi":"10.1016/j.cpt.2023.08.003","DOIUrl":"10.1016/j.cpt.2023.08.003","url":null,"abstract":"<div><h3>Background</h3><p>Large cancer registries help analyze the prognosis of rare malignancies, such as advanced vulvar cancer. This study aimed to compare the overall survival (OS) rates of patients with metastatic vulvar cancer who had undergone chemoradiotherapy and radiotherapy alone and identify prognostic factors using data from the Surveillance, Epidemiology, and End Results (SEER) registry.</p></div><div><h3>Methods</h3><p>In this retrospective cohort study, we used the SEER database to identify patients with metastatic vulvar cancer diagnosed between 2000 and 2019. Propensity score matching was performed to balance the covariates. Kaplan–Meier curves and Cox models were used to analyze OS.</p></div><div><h3>Results</h3><p>A total of 685 patients were included and divided into chemoradiotherapy and radiotherapy groups, and 400 patients were included after propensity score matching. The chemoradiotherapy group had higher OS in the matched cohort (hazard ratio [HR] = 0.7367; 95% confidence interval [CI]: 0.5906–0.9190; <em>P</em> = 0.0049) than the radiotherapy group, which was similar to that in the pre-matched cohort (<em>P</em> < 0.0001). Patients who had undergone surgery + radiotherapy with or without chemotherapy showed higher OS rates than those who had received radiotherapy with or without chemotherapy for patients aged <75 years and local tumor excision/destruction or surgical removal of the primary site was the recommended surgical choice (<em>P</em> < 0.05). Chemoradiotherapy is sufficient for patients ≥75 years of age.</p></div><div><h3>Conclusions</h3><p>Patients with metastatic vulvar cancer should undergo surgery if they can tolerate it. Adjuvant chemoradiotherapy should be encouraged because this treatment modality was associated with higher OS than radiotherapy alone.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 195-204"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000502/pdfft?md5=ba5d57911f6f16cb4429e235c04b3aa5&pid=1-s2.0-S2949713223000502-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78276324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of PD-1/PD-L1 inhibitors on survival in stage III non-small-cell lung cancer: A systematic review PD-1/PD-L1 抑制剂对 III 期非小细胞肺癌患者生存期的影响：系统综述

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/j.cpt.2023.09.004

Petros Roussos, Magdalini Migkou

{"title":"Impact of PD-1/PD-L1 inhibitors on survival in stage III non-small-cell lung cancer: A systematic review","authors":"Petros Roussos, Magdalini Migkou","doi":"10.1016/j.cpt.2023.09.004","DOIUrl":"10.1016/j.cpt.2023.09.004","url":null,"abstract":"<div><h3>Background</h3><p>Lung cancer is the leading cause of cancer-related death, and non-small-cell lung cancer (NSCLC) is the predominant subtype. Programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are widely used to treat stage IV NSCLC. This study systematically reviewed the literature to clarify the impact of PD-1/PD-L1 inhibitor treatment on the survival of patients with stage III NSCLC.</p></div><div><h3>Methods</h3><p>Randomized phase III clinical trials of PD-1/PD-L1 inhibitors administered to patients with stage III NSCLC that were written in English and published between November 2012 and November 2022 were eligible for review. The sources of information were the MEDLINE database (last consulted on December 26, 2022), ScienceDirect website (last consulted on December 26, 2022), and CENTRAL register (last consulted on December 27, 2022). The outcomes of interest were overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and event-free survival (EFS). Risk of bias assessments were performed according to the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. The findings have been assessed for certainty according to the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) guidelines.</p></div><div><h3>Results</h3><p>Fourteen eligible studies and 2788 participants were included in the review. The key characteristics used to group the participants were disease histology, percentage of PD-L1 expression in cancer cells, and timeline of therapy. OS and PFS were improved (risk ratio [RR]: 0.85; 95% confidence interval [CI]: 0.75–0.96 and RR: 0.75; 95% CI: 0.70–0.86, respectively) based on the use of PD-L1 inhibitors after chemoradiation and OS was improved using first-line PD-1 inhibitors plus chemotherapy in non-squamous NSCLC (RR: 0.40; 95% CI: 0.17–0.95), with the GRADE results indicating moderate quality of evidence.</p></div><div><h3>Conclusion</h3><p>This review highlights the OS and PFS benefits of PD-L1 inhibitors in stage III NSCLC when used after chemoradiation and OS benefits of first-line PD-1 inhibitors added to chemotherapy in non-squamous stage III disease.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 155-163"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294971322300054X/pdfft?md5=4c555b7c74c1e9642328e6b71e324039&pid=1-s2.0-S294971322300054X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135389593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and future perspectives on the regulation and functions of miR-545 in cancer development miR-545 在癌症发展中的调控和功能的现状与未来展望

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/j.cpt.2023.09.001

Jinze Shen, Xinming Su, Qurui Wang, Yufei Ke, Tianyu Zheng, Yunan Mao, Zehua Wang, Jingyin Dong, Shiwei Duan

{"title":"Current and future perspectives on the regulation and functions of miR-545 in cancer development","authors":"Jinze Shen, Xinming Su, Qurui Wang, Yufei Ke, Tianyu Zheng, Yunan Mao, Zehua Wang, Jingyin Dong, Shiwei Duan","doi":"10.1016/j.cpt.2023.09.001","DOIUrl":"10.1016/j.cpt.2023.09.001","url":null,"abstract":"<div><p>Micro ribonucleic acids (miRNAs) are a highly conserved class of single-stranded non-coding RNAs. Within the miR-545/374a cluster, miR-545 resides in the intron of the long non-coding RNA (lncRNA) <em>FTX</em> on Xq13.2. The precursor form, pre-miR-545, is cleaved to generate two mature miRNAs, miR-545-3p and miR-545-5p. Remarkably, these two miRNAs exhibit distinct aberrant expression patterns in different cancers; however, their expression in colorectal cancer remains controversial. Notably, miR-545-3p is affected by 15 circular RNAs (circRNAs) and 10 long non-coding RNAs (lncRNAs), and it targets 27 protein-coding genes (PCGs) that participate in the regulation of four signaling pathways. In contrast, miR-545-5p is regulated by one circRNA and five lncRNAs, it targets six PCGs and contributes to the regulation of one signaling pathway. Both miR-545-3p and miR-545-5p affect crucial cellular behaviors, including cell cycle, proliferation, apoptosis, epithelial-mesenchymal transition, invasion, and migration. Although low miR-545-3p expression is associated with poor prognosis in three cancer types, studies on miR-545-5p are yet to be reported. miR-545-3p operates within a diverse range of regulatory networks, thereby augmenting the efficacy of cancer chemotherapy, radiotherapy, and immunotherapy. Conversely, miR-545-5p enhances immunotherapy efficacy by inhibiting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression. In summary, miR-545 holds immense potential as a cancer biomarker and therapeutic target. The aberrant expression and regulatory mechanisms of miR-545 in cancer warrant further investigation.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 142-154"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000514/pdfft?md5=9e5c92ec4875e6931dceda6cb3c4ade8&pid=1-s2.0-S2949713223000514-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74087025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Common endocrine system adverse events associated with immune checkpoint inhibitors 与免疫检查点抑制剂相关的常见内分泌系统不良事件

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/j.cpt.2023.11.005

Ying Li , Junfeng Zhao , Yue Wang , Yali Xu , Ruyue Li , Ying Zhao , Xue Dong , Xiujing Yao , Yintao Li

{"title":"Common endocrine system adverse events associated with immune checkpoint inhibitors","authors":"Ying Li , Junfeng Zhao , Yue Wang , Yali Xu , Ruyue Li , Ying Zhao , Xue Dong , Xiujing Yao , Yintao Li","doi":"10.1016/j.cpt.2023.11.005","DOIUrl":"10.1016/j.cpt.2023.11.005","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs), a novel anti-tumor therapeutic modality, are monoclonal antibodies targeting certain immune checkpoints (ICs) that reactivate T cells to achieve anti-tumor immunity by targeting, binding, and blocking ICs. Targeted inhibitory antibodies against the ICs cytotoxic T-lymphocyte antigen and programmed death receptor-1 have demonstrated efficacy and durable anti-tumor activity in patients with cancer. ICs may prevent autoimmune reactions. However, ICIs may disrupt ICs properties and trigger autoimmune-related adverse reactions involving various organ systems including the cardiovascular, pulmonary, gastrointestinal, renal, musculoskeletal, dermal, and endocrine systems. Approximately 10% of patients with damage to target organs such as the thyroid, pituitary, pancreas, and adrenal glands develop endocrine system immune-related adverse events (irAEs) such as thyroid dysfunction, pituitary gland inflammation, diabetes mellitus, and primary adrenal insufficiency. However, the symptoms of immunotherapy-associated endocrine system irAEs may be nonspecific and similar to those of other treatment-related adverse reactions, and failure to recognize them early may lead to death. Timely detection and treatment of immunotherapy-associated endocrine irAEs is essential to improve the efficacy of immunotherapy, prognosis, and the quality of life of patients. This study aimed to review the mechanisms by which ICIs cause endocrine irAEs providing guidance for the development of appropriate management protocols. Here, we discuss (1) the biological mechanisms of ICs in tumorigenesis and progression, focusing on cytotoxic T-lymphocyte antigen and programmed cell death-1/programmed cell death-ligand 1; and (2) the epidemiology, clinical symptoms, diagnosis, and treatment of four immunotherapy-related endocrine complications.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 164-172"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000940/pdfft?md5=9b567190c1c0ea502bbe5918ef7f6a38&pid=1-s2.0-S2949713223000940-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138622530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heavy metal exposure as a risk factor in oral cancer 重金属暴露是口腔癌的一个风险因素

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/j.cpt.2024.05.002

Raja Kamalesh, Anbalagan Saravanan

引用次数: 0

Cover 封面

Cancer pathogenesis and therapy Pub Date : 2024-07-01 DOI: 10.1016/S2949-7132(24)00033-8

引用次数: 0